Avantra Family Wealth Inc. Purchases Shares of 1,809 Johnson & Johnson (NYSE:JNJ)

Avantra Family Wealth Inc. purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 1,809 shares of the company’s stock, valued at approximately $262,000.

Several other large investors have also added to or reduced their stakes in the company. Journey Strategic Wealth LLC grew its stake in Johnson & Johnson by 0.3% during the 4th quarter. Journey Strategic Wealth LLC now owns 7,038,858 shares of the company’s stock valued at $1,017,960,000 after purchasing an additional 21,959 shares during the last quarter. Sylvest Advisors LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth about $793,000. SYM FINANCIAL Corp boosted its stake in shares of Johnson & Johnson by 16.0% in the fourth quarter. SYM FINANCIAL Corp now owns 8,050 shares of the company’s stock worth $1,164,000 after buying an additional 1,113 shares during the last quarter. Comprehensive Financial Consultants Institutional Inc. boosted its stake in shares of Johnson & Johnson by 4.0% in the fourth quarter. Comprehensive Financial Consultants Institutional Inc. now owns 28,267 shares of the company’s stock worth $4,088,000 after buying an additional 1,078 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. boosted its stake in shares of Johnson & Johnson by 3.3% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 68,534 shares of the company’s stock worth $9,911,000 after buying an additional 2,221 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $153.54 on Wednesday. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The stock has a market cap of $369.66 billion, a PE ratio of 23.09, a P/E/G ratio of 2.44 and a beta of 0.52. The stock has a 50 day moving average price of $147.53 and a 200 day moving average price of $156.10.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter last year, the firm earned $2.29 earnings per share. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.23%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent research reports. Leerink Partners lowered their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Wells Fargo & Company lowered their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Bank of America lowered their price target on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research report on Thursday, January 23rd. Wolfe Research began coverage on Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $170.67.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.